Yongsheng Wang

机构：Lanzhou University of Technology, Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Shandong Tumor Hospital, Sichuan Cancer Hospital, Shandong First Medical University, Lanzhou University · ORCID：0009-0008-1576-283X

发表论文 92 篇 · 总被引 1615 次 · h-index 25

代表论文

• The PI3K/Akt/mTOR Pathway: Immuno-Metabolic Orchestration in IR/MASH-Associated Hepatocellular Carcinoma (2025 · International Journal of Biological Sciences · 被引 22)
• Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations. (2025 · Journal of Clinical Oncology · 被引 8)
• Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors (2025 · iScience · 被引 4)
• Real-world effectiveness of goserelin 10.8-mg compared to goserelin 3.6-mg in premenopausal and perimenopausal Chinese patients with hormone receptor positive breast cancer: a cohort study (2025 · Journal of the National Cancer Center · 被引 2)
• Intake of one-carbon metabolism nutrients and risk of rheumatoid arthritis: a prospective UK biobank cohort study (2025 · European Journal of Nutrition · 被引 1)
• Case report: Anlotinib plus oral etoposide: a potential salvage therapy based on insights from EGFR-TKI-resistant SCLC transformation PDX and clinical settings (2025 · Frontiers in Oncology · 被引 1)